Yes, it can be combined with corticosteroids or immunomodulators when a clinician deems a multi-drug approach necessary. However, overlapping 5-ASA products should be avoided to prevent excess dosing.
Severe, persistent abdominal pain may signal pancreatitis or a serious ulcerative colitis flare. Seek urgent medical assessment to determine the cause and appropriate management.
All mesalazine products contain the same active ingredient, but formulations differ in release mechanisms (e.g., delayed-release vs. pH-dependent). Asacol uses an enteric coating that targets release in the colon, which may affect tolerability and convenience.
Yes, Asacol is a prescription medicine, so you should carry the original prescription label and a copy of the prescribing clinician’s note. Check the destination country’s import rules for prescription drugs.
Taking Asacol with the evening meal can reduce gastric upset, but the tablet’s enteric coating means food does not affect its delivery to the colon. Consistency with meals helps maintain a routine.
Mesalazine can occasionally cause mild elevations in liver enzymes or alterations in blood counts. Regular monitoring helps detect these changes early, allowing dose adjustment if needed.
Patients with reduced renal function should have their kidney parameters checked regularly. Dose modifications may be required, and the prescriber will decide based on the severity of impairment.
Clinical improvement is often observed within 2-4 weeks, but full remission may require several months of consistent therapy.
Do not flush them down the toilet. Return unused tablets to a pharmacy’s medication-return service or follow local NHS guidance for safe disposal.
Asacol is a prescription-only medication (POM) used in the United Kingdom for the management of ulcerative colitis, a chronic inflammatory condition of the colon. The active ingredient in Asacol is mesalazine (also known as 5-aminosalicylic acid or 5-ASA). It is supplied as a 400 mg oral tablet and is marketed in the UK by Ferring Pharmaceuticals. As a member of the digestive-health therapeutic class, Asacol works locally within the gastrointestinal tract to reduce inflammation and help maintain remission of ulcerative colitis.
Mesalazine belongs to the 5-ASA family of drugs. After the enteric-coated tablet dissolves in the terminal ileum and colon, mesalazine is released directly onto the inflamed mucosa. Its anti-inflammatory actions include:
These mechanisms collectively dampen the immune response that drives ulcerative colitis, providing relief from symptoms and helping to keep the disease under control.
Asacol is approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for the following indication:
The medication is intended for patients who require a localized anti-inflammatory effect within the large intestine and is not indicated for Crohn’s disease or other gastrointestinal disorders.
Some clinical studies have explored mesalazine in conditions beyond its approved label, notably Crohn’s disease affecting the colon. While modest benefits have been reported in small trials, the evidence is insufficient for regulatory approval in the UK. Consequently, using Asacol for Crohn’s disease would be considered off-label and should only occur under specialist supervision, with a clear assessment of risks and benefits.
Disclaimer: Off-label use of any medication must be guided by a qualified healthcare professional and is not recommended without a thorough, individualized risk assessment.
Who may benefit: Adults with confirmed mild-to-moderate ulcerative colitis who require an anti-inflammatory agent acting locally in the colon.
Absolute contraindications
Relative contraindications / special considerations
Patients with a history of pancreatitis, blood dyscrasias, or severe allergic reactions to salicylates should discuss alternative therapies with their clinician.
These effects are generally transient and lessen with continued therapy. Taking the tablet with food can help minimise gastrointestinal discomfort.
If any of these serious symptoms develop, seek immediate medical attention.
Patients should provide a complete medication list-including over-the-counter drugs and herbal supplements-to their prescriber.
Routine monitoring supports safe long-term use:
If any laboratory abnormality emerges, the prescriber may adjust the dose or discontinue therapy.
This article provides educational information about Asacol and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
